Industry News (Blood Transfusion)

Vitex Files To Commence Trials of New "Universal" Plasma

Published in AIDS Weekly, August 23rd, 1999

V.I. Technologies, Inc., Melville, New York, announced that the company has filed an Investigational New Drug (IND) amendment with the U.S. Food and Drug Administration (FDA) to commence trials of a new version of PLAS+SD which removes the antibodies that cause plasma to be blood-type specific.

PLAS+SD is a transfusion plasma product that uses Vitex's solvent detergent process to remove lipid enveloped viruses including HIV, hepatitis C, and hepatitis B. Today, all plasma must be typed before it is administered to a patient.

The next generation PLAS+SD removes blood-type specific antibodies (isoagglutinins), making it possible to use this product as...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of AIDS Weekly

Source: AIDS Weekly (1999-08-23)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry